{"id":1473,"date":"2024-07-08T14:48:26","date_gmt":"2024-07-08T12:48:26","guid":{"rendered":"https:\/\/semmelweis.hu\/esk\/?p=1473"},"modified":"2024-07-08T14:48:50","modified_gmt":"2024-07-08T12:48:50","slug":"a-2023-as-oszi-kampanyok-soran-beadott-covid-19-vakcinak-eredmenyessege-europaban","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/esk\/2024\/07\/08\/a-2023-as-oszi-kampanyok-soran-beadott-covid-19-vakcinak-eredmenyessege-europaban\/","title":{"rendered":"A 2023-as \u0151szi kamp\u00e1nyok sor\u00e1n beadott COVID-19 vakcin\u00e1k eredm\u00e9nyess\u00e9ge Eur\u00f3p\u00e1ban:"},"content":{"rendered":"

VEBIS<\/strong>1<\/sup><\/strong> alapell\u00e1t\u00e1si teszt-negat\u00edv m\u00f3dszerrel v\u00e9gzett vizsg\u00e1lat eredm\u00e9nyei,\u00a02023 szeptembere \u00e9s 2024 janu\u00e1r k\u00f6z\u00f6tt<\/strong><\/span><\/h3>\n

\"\"<\/p>\n

Eur\u00f3p\u00e1ban a COVID-19 \u00e9s influenza v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9t a forgalomba hozatali enged\u00e9ly megszerz\u00e9s\u00e9t k\u00f6vet\u0151en az Eur\u00f3pai Betegs\u00e9gmegel\u0151z\u00e9si \u00e9s J\u00e1rv\u00e1nyv\u00e9delmi K\u00f6zpont (ECDC) k\u00f6zrem\u0171k\u00f6d\u00e9s\u00e9vel l\u00e9trehozott VEBIS*<\/sup> multicentrikus vizsg\u00e1latban \u00e9rt\u00e9kelj\u00fck. A jelen vizsg\u00e1latban a PCR vizsg\u00e1lattal igazolt, t\u00fcneteket okoz\u00f3 fert\u0151z\u00e9ssel szemben becs\u00fclt\u00fck meg a COVID-19 vakcina eredm\u00e9nyess\u00e9get (VE) 2023 szeptember \u00e9s 2024 janu\u00e1r k\u00f6z\u00f6tti id\u0151szak eredm\u00e9nyei alapj\u00e1n. Az alapell\u00e1t\u00e1si szinten 11 orsz\u00e1g kutat\u00e1si helysz\u00edn\u00e9nek adatait elemezt\u00fck.<\/p>\n

A 2023 \u0151szi szezonban a r\u00e9sztvev\u0151 orsz\u00e1gok olt\u00e1si kamp\u00e1nyai sor\u00e1n az olt\u00e1sban r\u00e9szes\u00fcl\u0151k t\u00f6bbs\u00e9ge XBB.1.5 vakcin\u00e1t kapott. \u00a0A vizsg\u00e1latba 1057 esetet \u00e9s 4397 kontrollt vontunk be. A VE becsl\u00e9se teszt-negat\u00edv m\u00f3dszerrel eset-kontroll elrendez\u00e9ssel t\u00f6rt\u00e9nt, a vizsg\u00e1lat eredm\u00e9nyeit k\u00fcl\u00f6nb\u00f6z\u0151 c\u00e9lcsoportok szerint \u00f6sszes\u00edtett\u00fck. Az olt\u00e1s eredm\u00e9nyess\u00e9ge a teljes popul\u00e1ci\u00f3ban 40% volt, a t\u00fcnetek megjelen\u00e9se el\u0151tt 6 h\u00e9ten bel\u00fcl oltottak alcsoportj\u00e1ban 48%, m\u00edg a t\u00fcneteket megel\u0151z\u0151 6-14 h\u00e9tben olt\u00e1sban r\u00e9szes\u00fcl\u0151k alcsoportj\u00e1ban 29%.<\/p>\n

\u00d6sszess\u00e9g\u00e9ben az eredm\u00e9nyek r\u00e1mutattak, hogy 2023 \u0151szi kamp\u00e1nyok sor\u00e1n a meghat\u00e1rozott c\u00e9lcsoportoknak beadott COVID-19 olt\u00f3anyagok klinikailag jelent\u0151s hat\u00e1soss\u00e1got mutattak a SARS-CoV-2 fert\u0151z\u00e9s ellen az olt\u00e1st k\u00f6vet\u0151 3 h\u00f3napban, de a legeredm\u00e9nyesebbnek a t\u00fcnetek megjelen\u00e9se el\u0151tt 6 h\u00e9ttel beadott olt\u00e1st tal\u00e1ltuk. A teljes szezon adatainak k\u00e9s\u0151bbi vizsg\u00e1lata lehet\u0151s\u00e9get ad tov\u00e1bbi alvari\u00e1nsok szerinti COVID-19 VE becsl\u00e9sek k\u00e9sz\u00edt\u00e9s\u00e9hez, hozz\u00e1j\u00e1rul a v\u00e9d\u0151olt\u00e1s eredm\u00e9nyess\u00e9g cs\u00f6kken\u00e9s\u00e9nek jobb meg\u00e9rt\u00e9s\u00e9hez \u00e9s inform\u00e1ci\u00f3val szolg\u00e1l az eml\u00e9keztet\u0151 olt\u00e1sok tov\u00e1bbi c\u00e9lkit\u0171z\u00e9seihez.<\/p>\n

* Vaccine Effectiveness, Burden and Impact Studies<\/span><\/p>\n

Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023\u2013January 2024<\/u><\/strong><\/span><\/h3>\n

Charlotte Laniece Delaunay<\/em> (Epiconcept),
\n<\/em>Marine Maurel<\/em> (Epiconcept),
\n<\/em>Esther Kissling <\/em>(Epiconcept),
\n<\/em>Beatrix Oroszi <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest),
\n<\/em>Gerg\u0151 T\u00fari <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest)
\n<\/em>and the VEBIS study group<\/em><\/p>\n

Abstract<\/span>
\n<\/u><\/strong>In Europe, after approval, the effectiveness of COVID-19 and influenza vaccines is being measured in the VEBIS*<\/sup> study, a collaboration with the European Centre for Disease Prevention and Control. Based on results from September 2023 to January 2024, we estimated the COVID-19 vaccine effectiveness (VE) against symptomatic infection confirmed by PCR testing. At the primary care level, data from study sites of 11 European countries were analysed.<\/p>\n

In the 2023 autumn season, during the vaccination campaigns of the participating countries, the majority of those vaccinated received the XBB.1.5 vaccine. 1057 cases and 4397 controls were included in the study. For VE estimates we used a test-negative case control design, the results of the study were aggregated according to different target groups. The vaccine effectiveness was 40% in the entire population, 48% in the subgroup of those vaccinated within 6 weeks before the onset of symptoms, and 29% in the subgroup of those vaccinated 6-14 weeks before the onset of symptoms.<\/p>\n

Overall, our findings indicate that COVID-19 vaccines administered to target groups during the autumn 2023 campaigns showed clinically significant effectiveness against SARS-CoV-2 infection in the 3 months following vaccination, but the most effective vaccine was found to be administered 6 weeks before the onset of symptoms. Future analysis of the full season data enables further provision of subvariant estimates of COVID-19 vaccine effectiveness, contributing to a better understanding of the decline in vaccine effectiveness and informing further objectives for booster vaccination.<\/p>\n

* Vaccine Effectiveness, Burden and Impact Studies<\/span><\/p>\n

Vaccine, 2024, ISSN 0264-410X, https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.067<\/a>.
\n<\/span><\/i>https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X24006443<\/p>\n

 <\/p>\n

K\u00e9sz\u00edtette az \"\"\u00a0<\/em><\/span><\/p>\n

RRF-2.3.1-21-2022-00006 Eg\u00e9szs\u00e9gbiztons\u00e1g Nemzeti Laborat\u00f3rium projekt <\/em><\/span>\"\"<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

VEBIS1 alapell\u00e1t\u00e1si teszt-negat\u00edv m\u00f3dszerrel v\u00e9gzett vizsg\u00e1lat eredm\u00e9nyei,\u00a02023 szeptembere \u00e9s 2024 janu\u00e1r k\u00f6z\u00f6tt Eur\u00f3p\u00e1ban a COVID-19 \u00e9s influenza v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9t a forgalomba hozatali enged\u00e9ly megszerz\u00e9s\u00e9t k\u00f6vet\u0151en az Eur\u00f3pai Betegs\u00e9gmegel\u0151z\u00e9si \u00e9s J\u00e1rv\u00e1nyv\u00e9delmi K\u00f6zpont (ECDC) k\u00f6zrem\u0171k\u00f6d\u00e9s\u00e9vel l\u00e9trehozott VEBIS* multicentrikus vizsg\u00e1latban \u00e9rt\u00e9kelj\u00fck. A jelen vizsg\u00e1latban a PCR vizsg\u00e1lattal igazolt, t\u00fcneteket okoz\u00f3 fert\u0151z\u00e9ssel szemben becs\u00fclt\u00fck meg a COVID-19 vakcina eredm\u00e9nyess\u00e9get …<\/p>\n","protected":false},"author":102284,"featured_media":1474,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-1473","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cikk-osszefoglalok"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/1473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/users\/102284"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/comments?post=1473"}],"version-history":[{"count":1,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/1473\/revisions"}],"predecessor-version":[{"id":1475,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/1473\/revisions\/1475"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media\/1474"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media?parent=1473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/categories?post=1473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/tags?post=1473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}